Portal de Periódicos da CAPES

Cracking the ring of Edwards Perimount bioprosthesis with ultrahigh pressure balloons prior to transcatheter valve in valve implantation

2014; Elsevier BV; Volume: 176; Issue: 3 Linguagem: Inglês

10.1016/j.ijcard.2014.07.175

1874-1754

Daniel Tanase, Jochen Grohmann, Stefan Schubert, Frank Uhlemann, Andreas Eicken, Peter Ewert,

Mechanical Circulatory Support Devices

Percutaneous pulmonary valve implantation (PPVI) has emerged to the preferred mode of treatment for right ventricular outflow tact (RVOT) valved conduit dysfunction in some centers1, 2. While homografts and distensible heterograft conduits are usually dilatable to larger diameters, even if considerably shrunk and calcified, non-distensible Dacron- or PTFE-conduits and mounted bioprostheses cannot be augmented in diameter. So far in these patients surgical replacement is the only treatment option if the diameters of the implants are too small. We report on in vitro conceptional testing followed by catheter interventional treatment (PPVI) of three patients with a stenotic Edwards Perimount bioprosthesis (Edwards Lifesciences Corporation, Irvine, US) in the RVOT. Erratum to "Cracking the ring of Edwards Perimount bioprosthesis with ultrahigh pressure balloons prior to transcatheter valve in valve implantation" [Int. J. Cardiol. 176 (2014) 1048–1049]International Journal of CardiologyVol. 197PreviewThe correct affiliations of the authors are the following: Full-Text PDF